Oculis OCS 深 滬
等待開盤 10-28 09:30:00 美东时间
7.83
-0.130
-1.63%
華盛通- 最 高8.145
- 今 開7.92
- 成交量 18.93万股
- 最 低 7.68
- 昨 收 7.96
- 總市值 4.82亿
- 52周最高 34.475
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 7.11
- 委 比 33.33%
- 總股本 6158.81万
- 歷史最高 34.475
- 量 比 0.60
- 振 幅 5.84%
- 歷史最低 6.26
- 每 手 1
- 風險率 7.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.37%！摩根士丹利上调西部数据(WDC)目标价至668美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持西部数据"超配"评级，目标价从643美元升至668美元；摩根大通：维持西部数据"超配"评级，目标价从600美元升至650美元
10-26 12:30
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
10-23 18:32
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Oculis Holding AG announced the completion of randomization in the PREDICT-1 trial for Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant linked to enhanced response. Licaminlimab aims to address an unmet need for ~1.5 million U.S. patients with moderate-to-severe DED. Topline results are expected by year-end 2026. The trial evaluates efficacy ...
10-19 06:00
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
<p>Oculis Holding AG has completed enrollment in the PREDICT-1 trial of Licaminlimab, a gene-targeted precision medicine for dry eye disease (DED), with 176 patients, 2/3 of whom have a specific TNFR1 genotype linked to improved clinical response. Licaminlimab aims to address unmet needs in DED treatment by targeting patients with TNFR1-mediated disease, potentially offering the first precision therapy for approximately 1.5 million affected indiv...
10-19 06:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- A notification regarding the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors is attached. The notification pertains to Riad Sherif and was issued on October 5, 2026.</p>
10-08 20:05
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis Holding AG has joined the National Multiple Sclerosis Society’s Campaign to End MS as the industry partner focusing on Vision. The 5-year campaign aims to accelerate research breakthroughs, improve access to care, and enhance the lives of MS patients. Oculis is developing Privosegtor, a potential neuroprotective therapy for optic neuritis and acute MS relapses, with ongoing clinical trials and plans for IND submission. The partnership refl...
10-01 06:00
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema. The biotechnology company aims to advance the investigational therapy into clinic...
09-24 23:41
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank cut the price target for Xenon Pharmaceuticals Inc (NASDAQ:XENE) from $90 to $46. Deutsche Bank ...
09-18 20:31
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $26 to $39.
09-18 18:53
